2024 proved to be a pivotal year for Basilea, marked by the commencement of the fosmanogepix Phase 3 trials, along with funding secured from BARDA, which helps to facilitate a smooth development pathway. Basilea is well-positioned financially, while Cresemba remains firmly in its growth phase. The final piece of the puzzle for us was identifying the commercial partner for Zevtera (ceftobiprole) in the key US market. Innoviva Specialty Therapeutics (IST) appears to be a relevant and highly motivated partner with a complementary portfolio of antibiotics. Finally, we look forward to further progress in the pipeline, with fosmanogepix now in Phase 3, and we are anticipating that BAL2062 will enter the clinic in 2026, with the LptA inhibitor programme also moving forward.
